Drug Trial Radar · NCT05280548
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
104
Actual
Start
May 3, 2022
Primary completion
May 22, 2026
Study completion Dec 6, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an 18-month, multicenter, randomized, active-control, parallel-group Phase 3 study, in which participants will be randomized to venglustat versus standard of care therapy (agalsidase alfa, agalsidase beta, or migalastat) to evaluate the effect of venglustat on left ventricular mass index (LVMI) in adult participants with Fabry disease and left ventricular hypertrophy. * Study visits will take place approximately every 3 to 6 months * Participants who complete the randomized period may continue to the long-term extension (LTE) to receive venglustat for up to additional 45 months with the total study duration up to 5.3 years maximum.
Conditions
- Fabry Disease
Interventions
Venglustat (GZ402671)Drug
Tablet; Oral
Agalsidase alfaDrug
Concentrate for solution for infusion; IV infusion
Agalsidase beta (GZ419828)Drug
Powder for concentrate for solution for infusion; IV infusion
MigalastatDrug
Hard capsules; Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Slope of left ventricular mass index as measured by cardiac magnetic resonance imaging (MRI) (central reading)Time frame: from baseline to 18 months
Locations
54 sites in 19 countries. Site status is shown where the registry gives one.
University of Alabama -The Kirklin Clinic- Site Number : 8400010
Birmingham, Alabama
University of California Los Angeles Medical Center- Site Number : 8400008
Los Angeles, California
Emory University School of Medicine - Atlanta- Site Number : 8400009
Atlanta, Georgia
Ann & Robert H. Lurie Children's Hospital of Chicago- Site Number : 8400005
Chicago, Illinois
Maryam Banikazemi, MD- Site Number : 8400001
Hawthorne, New York
Renal Disease Research Institute- Site Number : 8400012
Dallas, Texas
University of Utah Health Hospital- Site Number : 8400006
Salt Lake City, Utah
Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)- Site Number : 8400004
Fairfax, Virginia
Investigational Site Number : 0400001
Graz, Austria
Investigational Site Number : 1240003
Calgary, Alberta, Canada
Investigational Site Number : 1240006
Edmonton, Alberta, Canada
Investigational Site Number : 1240002
Vancouver, British Columbia, Canada
Investigational Site Number : 1240005
Toronto, Ontario, Canada
Investigational Site Number : 1560002
Beijing, China
Investigational Site Number : 1560005
Beijing, China
Investigational Site Number : 1560001
Chengdu, China
Investigational Site Number : 1560007
Guangzhou, China
Investigational Site Number : 1560003
Shanghai, China
Investigational Site Number : 2030001
Prague, Czechia
Investigational Site Number : 2080001
Copenhagen, Denmark
Investigational Site Number : 2500001
Garches, France
Investigational Site Number : 2760003
Berlin, Germany
Investigational Site Number : 2760004
Hochheim am Main, Germany
Investigational Site Number : 2760005
Mainz, Germany
Investigational Site Number : 2760001
Würzburg, Germany
Investigational Site Number : 3000002
Athens, Greece
Investigational Site Number : 3000003
Athens, Greece
Investigational Site Number : 3000001
Heraklion, Greece
Investigational Site Number : 3800004
Bologna, Italy
Investigational Site Number : 3800001
Milan, Lombardy, Italy
Investigational Site Number : 3800002
Naples, Napoli, Italy
Investigational Site Number : 3800003
Naples, Napoli, Italy
Investigational Site Number : 3920004
Fukuoka, Japan
Investigational Site Number : 3920001
Tokyo, Japan
Investigational Site Number : 3920006
Sapporo, Hokkaido, Japan
Investigational Site Number : 3920007
Kagoshima, Kagoshima-ken, Japan
Investigational Site Number : 3920003
Kagoshima, Kagoshima-ken, Japan
Investigational Site Number : 3920005
Kawasaki, Kanagawa, Japan
Investigational Site Number : 3920002
Sendai, Miyagi, Japan
Investigational Site Number : 5280001
Amsterdam, Netherlands
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.